Medicare Drug Coverage Lookup

How Part D tiers work

Most Medicare Part D plans use a five-tier formulary system. The tier determines your cost-sharing structure (flat copay vs. coinsurance) and how the drug is treated relative to other options on your plan.

• Tier 1 — Preferred generics: Preferred generics — lowest copay (often $0–$5)
• Tier 2 — Generics: Generics — low copay ($5–$15)
• Tier 3 — Preferred brand: Preferred brand — moderate copay ($30–$50) or 25% coinsurance
• Tier 4 — Non-preferred: Non-preferred — higher copay ($90–$100) or 33–50% coinsurance
• Tier 5 — Specialty: Specialty — 25–33% coinsurance, often requires prior authorization

The new $2,000 annual cap

The most important change to Part D in years: starting January 2025, all Medicare Part D enrollees have a $2,000 annual cap on out-of-pocket spending for covered drugs. Hit the cap, and you pay $0 for the rest of the calendar year. The cap resets every January 1.

For specialty drug users, this is transformative. Drugs like Otezla, Tremfya, Imbruvica, and Humira used to result in $5,000–$10,000+ annual out-of-pocket spending under the old structure. Now the maximum is $2,000.

You can also opt into the Medicare Prescription Payment Plan, which spreads the $2,000 maximum across monthly installments — useful for high-cost drugs where the entire $2,000 would otherwise hit in January.

Common reasons a drug shows as "not covered" or restricted

• Statutory exclusion: Federal law excludes weight-loss drugs (mostly), fertility drugs, cosmetic drugs, and certain OTC medications from Part D.
• Prior authorization required: The drug is technically covered, but your prescriber must submit a PA form before the plan will pay. Most specialty drugs require PA.
• Step therapy: The plan requires you to try a less expensive alternative first. If the alternative fails or is contraindicated, the preferred drug is approved.
• Quantity limits: The plan caps the quantity per fill (e.g., 30-day supply only).

If your drug isn't covered or you've been denied

Three steps:

1. Request an exception: Your prescriber's office submits a formulary exception request to your Part D plan. The plan must respond within 72 hours (24 hours for urgent requests).
2. Appeal a denial: If the exception is denied, you have appeal rights — first redetermination, then independent review. CMS data shows that a meaningful share of Part D denials are reversed at the redetermination stage.
3. Switch plans during open enrollment: If your drug is consistently restricted on your current plan, the next annual open enrollment (October 15–December 7) is your chance to switch to a plan with better coverage of your specific medications.

The Medicare drug price negotiation impact

The Inflation Reduction Act gave Medicare authority to directly negotiate prices with manufacturers for the highest-cost drugs without generic alternatives. The first negotiated prices took effect January 1, 2026, covering ten drugs including Eliquis, Xarelto, Jardiance, Januvia, Farxiga, and Imbruvica. The negotiated prices are typically 30–60% below the prior list prices.

The savings flow primarily to Medicare and indirectly to beneficiaries through lower premiums. For drugs on plans with coinsurance-based cost-sharing, beneficiaries also see direct savings — your 25% coinsurance on a $231 drug is much less than 25% on a $521 drug.

Round 2 of negotiated drugs — 15 more — will be announced in 2026 with prices effective in 2027. Round 3 expands further. The trajectory is meaningful for Medicare drug affordability.